VRTX

Vertex Pharmaceuticals Incorporated

495.08 USD

Last updated Oct 14, 16:13 UTC

Yesterday HIGH

$508.57

Yesterday LOW

$484.08

52w HIGH

$560.25

52w LOW

$402.58

EPS

4.73

PE

104.67

Next Earnings

Nov 2, 2026

Overview News Unusual Options Flow Government Trades Fundamentals

Vertex Pharmaceuticals Incorporated stock is down -4.7% since 30 days ago. The next earnings date is Nov 2, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 52.78% of the previous 35 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 7 CALLs, 3 PUTs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

13 Oct 15:31	21 Jan, 2028	490.00	CALL	3	27
13 Oct 15:49	15 Jan, 2027	510.00	CALL	10	210
13 Oct 15:59	30 Oct, 2026	495.00	PUT	30	61
13 Oct 16:18	18 Dec, 2026	450.00	CALL	13	57
13 Oct 16:36	17 Jun, 2027	630.00	CALL	54	53
13 Oct 18:24	23 Oct, 2026	510.00	CALL	331	557
14 Oct 13:40	17 Sep, 2027	420.00	PUT	10	0
14 Oct 13:49	19 Jan, 2029	410.00	CALL	2	0
14 Oct 15:38	17 Jun, 2027	600.00	PUT	4	4
14 Oct 15:54	15 Jan, 2027	510.00	CALL	10	210

Advanced Data Unlock

Benzinga Newsdesk

Tue Aug 4, 2026

TD Cowen Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $550

TD Cowen analyst Phil Nadeau maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $525 to $550.
Benzinga Newsdesk

Tue Aug 4, 2026

Cantor Fitzgerald Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $595

Cantor Fitzgerald analyst Carter Gould maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $590 to $595.
Benzinga Newsdesk

Mon Aug 3, 2026

Vertex Pharmaceuticals Raises FY2026 Sales Guidance from $12.950B-$13.100B to $13.100B-$13.200B vs $13.065B Est

Vertex Pharmaceuticals (NASDAQ:VRTX) raises FY2026 sales outlook from $12.950 billion-$13.100 billion to $13.100 billion-$13.200 billion vs $13.065 billion estimate.
Benzinga Newsdesk

Mon Aug 3, 2026

Vertex Pharmaceuticals Q2 Adj. EPS $4.73, Inline, Sales $3.334B Beat $3.232B Estimate

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.73 per share which met the analyst consensus estimate. This is a 4.65 percent increase over earnings of $4.52 per share from the same period last
Avi Kapoor

Mon Aug 3, 2026

Tyson Foods, Marriott And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, focus on earnings from Tyson Foods, Marriott, Universal Logistics, Williams Companies, and Vertex Pharmaceuticals.
Avi Kapoor

Mon Aug 3, 2026

Nasdaq Jumps 1% as Amazon Shares Surge: Investor Sentiment Improves, But Greed Index Remains in 'Fear' Zone

CNN Money Fear & Greed index improved while remaining in 'Fear' zone on Friday. Amazon up 15%, Apple down 7%.
Benzinga Newsdesk

Wed Jul 29, 2026

AbCellera Announces $28M Upfront Vertex Collaboration On Multispecific T-Cell Engagers For Autoimmune Diseases, Eligible For Milestone Payments And Tiered Royalties
Piero Cingari

Tue Jul 21, 2026

These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why

Seven small-cap stocks have surged as much as 123% in early July on buyouts, FDA developments, refinancing deals and short squeezes.
Benzinga Insights

Wed Jul 15, 2026

$1000 Invested In Vertex Pharmaceuticals 5 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 5 years by 7.55% on an annualized basis producing an average annual return of 19.41%. Currently, Vertex Pharmaceuticals has a market
Benzinga Newsdesk

Mon Jul 13, 2026

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $585

UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $545 to $585.

RBC Capital

Thu Oct 8, 16:10

buy

confirm
UBS

Mon Sep 28, 19:56

buy

confirm